Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.

@article{Teng2015PharmacologicIO,
  title={Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.},
  author={Pang-ning Teng and Nicholas W Bateman and Kathleen M. Darcy and Chad A. Hamilton and G. Larry Maxwell and Christopher J. Bakkenist and Thomas P. Conrads},
  journal={Gynecologic oncology},
  year={2015},
  volume={136 3},
  pages={
          554-61
        }
}
OBJECTIVE Significant reductions in gynecologic (GYN) cancer mortality and morbidity require treatments that prevent and reverse resistance to chemotherapy and radiation. The objective of this study was to determine if pharmacologic inhibition of key DNA damage response kinases in GYN cancers would enhance cell killing by platinum-based chemotherapy and radiation. METHODS A panel of human ovarian, endometrial and cervical cancer cell lines were treated with platinum drugs or ionizing… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Targeting the ATR-CHK1 Axis in Cancer Therapy

View 11 Excerpts
Method Support
Highly Influenced